Αποτελέσματα Αναζήτησης
12 Οκτ 2020 · With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
25 Φεβ 2015 · New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibril.
19 Μαρ 2015 · Overview of the New Oral Anticoagulants: The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for many indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxab...
In recent decades, oral anticoagulation therapy has evolved beyond vitamin K antagonists to include oral direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban). For the initial several years, different terms were used to describe this newer class of oral anticoagulants.
Oral direct inhibitors of thrombin and activated factor Xa are approved as new anticoagulant drugs. In contrast to vitamin K antagonists (VKA) and heparins, the new agents have single targets in the coagulation cascade and more predictable ...
18 Οκτ 2024 · Download PDF. Summary. Over the last decade, the advent of direct oral anticoagulants (DOACs) has rapidly changed the landscape of anticoagulation. In the early 2010s, DOACs became widely available for stroke prevention in atrial fibrillation and the treatment of venous thromboembolism.
19 Ιουν 2014 · New oral anticoagulants (NOAC) are becoming available as alternatives to warfarin to prevent systemic embolism in patients with non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolism.
